Contact Congress about S. 1186: Lower Drug Costs for Families Act

Drug companies could have to pay more back when prices rise faster than inflation. The bill uses a 2016 starting point instead of 2021 and also counts drug use in the private insurance market. It changes rebate rules for both Medicare Part B and Part D drugs.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Lower Drug Costs for Families Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.

Latest action on S. 1186: Read twice and referred to the Committee on Finance.

Who this affects: This bill mainly affects drug companies first, because it could raise the rebates they owe when prices go up too fast. It also affects Medicare, private health plans, and government agencies that calculate and collect those rebates. Families with prescription costs could feel indirect effects later if the policy changes premiums, plan spending, or drug pricing.

Why this matters: This matters because the bill could increase what drug companies owe when prices rise faster than inflation. Using 2016 instead of 2021 pulls in more years of price increases, so some drugs could face much larger rebates. The bill also reaches beyond Medicare by using commercial market data, which could influence pricing decisions more broadly. At the same time, the actual effect on premiums or out-of-pocket costs is unclear because the bill does not require savings to be passed on to patients.

Key provisions in S. 1186

• This bill would count some drug sales in the private insurance market when figuring inflation rebates. It changes how drug units are defined and counted to do that.
• For Medicare Part B drugs, the bill would use "billing units" instead of "units." It also lays out steps for counting total billing units across National Drug Codes, or NDCs, which are the ID numbers for drug products.
• Part B would not count drug units already paid for by Medicaid. That helps prevent overlap with Medicaid rebate duties.
• For Medicare Part D drugs, the bill would use the same unit count companies already use for Average Manufacturer Price, or AMP. They report that number through the Medicaid Drug Rebate program.
• Part D would leave out units paid for by Medicaid. It would also leave out units already covered by Part B inflation rebates and, starting in 2026, units sold with a 340B discount.

How Modern Action helps you take action on S. 1186

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1186

What is S. 1186?

Drug companies could have to pay more back when prices rise faster than inflation. The bill uses a 2016 starting point instead of 2021 and also counts drug use in the private insurance market. It changes rebate rules for both Medicare Part B and Part D drugs.

How do I support or oppose S. 1186?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1186?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 1186?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.